← All peptide profiles
Peptide profile Clinical research
Cagrilintide
Metabolic medicines
A long-acting amylin analogue being studied for weight-related indications. It is not an FDA-approved medicine; FDA’s 2026 GLP-1 guidance says it cannot be used in compounding under federal law.
01 What is Cagrilintide?
Start with the actual term.
A long-acting amylin analogue being studied for weight-related indications. It is not an FDA-approved medicine; FDA’s 2026 GLP-1 guidance says it cannot be used in compounding under federal law.
02 How to read the evidence
What the current guide can—and cannot—say.
This topic appears in human clinical research or active development. A clinical trial can provide important evidence, but participation in research or a promising study result is not the same as routine regulatory approval.
03 Why context matters
A mechanism or name is not a conclusion.
Look for the study phase, the condition being studied, the comparison group, the number of participants, and whether the findings have been peer reviewed. Those details determine what a result can actually show.
04 Potential research applications
Research area is not an approved use.
This guide places Cagrilintide within Metabolic medicines. That category helps readers orient themselves; it does not establish that any compound or product is effective, safe, available, or suitable for a particular condition or person.
05 Safety and adverse effects
Use the right record for the right question.
This profile does not present a generic adverse-effect list because safety findings depend on the exact product, formulation, study setting, population, and duration. Where a current official label or direct record is linked below, use that original source. Otherwise, the absence of a listed effect is not evidence that a risk is absent.
06 What we do not know
Keep uncertainty visible.
A trial result should not be read as a personal treatment recommendation. Development programs, approvals, and availability can change quickly.